Antimicrobial resistance comparison of Klebsiella pneumoniae pathogens isolated from intra-abdominal and urinary tract infections in different organs, hospital departments and regions of China between 2014 and 2017
- PMID: 32247662
- DOI: 10.1016/j.jmii.2020.03.009
Antimicrobial resistance comparison of Klebsiella pneumoniae pathogens isolated from intra-abdominal and urinary tract infections in different organs, hospital departments and regions of China between 2014 and 2017
Abstract
Background: We describe antibiotic resistance trends of Klebsiella pneumoniae pathogens, responsible for urinary tract infections (UTIs) and intra-abdominal infections (IAIs), isolated from different organs and tissues, hospital departments and Chinese regions between 2014 and 2017.
Methods: Resistances of UTIs and IAIs derived K. pneumoniae isolates from 17 hospitals in 7 Chinese regions to amikacin, imipenem, piperacillin-tazobactam, ertapenem, and cefepime were unequivocally established.
Results: Overall resistance rates of K. pneumoniae IAI isolates obtained from gallbladder and abscesses increased to amikacin (14.29-30.95%) and for liver, gallbladder, and abscesses to imipenem (14.29-38.10%), piperacillin-tazobactam (23.81-38.10%), and ertapenem (23.81-38.10%) in 2017, but were constant (20-30%) for K. pneumoniae isolates from UTIs from 2014 to 2017. In medical and surgical ICUs, resistance rates to all tested antibiotics rose to ∼60% for IAIs, which was also reflected in higher resistance rates of hospital acquired (HA) compared to community acquired (CA) infections. In medical ICUs resistance rates increased to 50-60% for amikacin, imipenem, and ertapenem for UTI-derived K. pneumoniae isolates in 2017. Resistance rates to all tested antibiotics were highest in the east Jiangzhe region of China, being ∼60% for K. pneumoniae isolates from IAIs and 40% for K. pneumoniae isolates from UTIs to ertapenem and imipenem, as well as > 40% for piperacillin-tazobactam in 2017.
Conclusion: In China, ICUs resistance rates to K. pneumoniae IAIs and UTIs isolates was increased in 2017 for all tested antimicrobials including carbapenems, which makes them no longer suitable for empiric treatment. In the east Jiangzhe region this was a general trend that was independent of the type of hospital department.
Keywords: Antibiotic resistance; Carbapenems; ESBL; Intra-abdominal infections; Klebsiella pneumoniae; Urinary tract infections.
Copyright © 2020. Published by Elsevier B.V.
Similar articles
-
Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.J Antimicrob Chemother. 2017 May 1;72(5):1364-1372. doi: 10.1093/jac/dkw574. J Antimicrob Chemother. 2017. PMID: 28122913
-
Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.BMC Infect Dis. 2017 Dec 18;17(1):776. doi: 10.1186/s12879-017-2873-z. BMC Infect Dis. 2017. PMID: 29254478 Free PMC article.
-
A 10 year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China.J Med Microbiol. 2013 Sep;62(Pt 9):1343-1349. doi: 10.1099/jmm.0.059816-0. Epub 2013 Jun 5. J Med Microbiol. 2013. PMID: 23741022
-
Antimicrobial Resistance of Hypervirulent Klebsiella pneumoniae: Epidemiology, Hypervirulence-Associated Determinants, and Resistance Mechanisms.Front Cell Infect Microbiol. 2017 Nov 21;7:483. doi: 10.3389/fcimb.2017.00483. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 29209595 Free PMC article. Review.
-
Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae.Front Cell Infect Microbiol. 2018 Jan 22;8:4. doi: 10.3389/fcimb.2018.00004. eCollection 2018. Front Cell Infect Microbiol. 2018. PMID: 29404282 Free PMC article. Review.
Cited by
-
Differences in molecular characteristics and expression of virulence genes in carbapenem-resistant and sensitive Klebsiella pneumoniae isolates in Ningbo, China.Front Microbiol. 2024 Feb 7;15:1356229. doi: 10.3389/fmicb.2024.1356229. eCollection 2024. Front Microbiol. 2024. PMID: 38389531 Free PMC article.
-
Clinical and resistance characterization of carbapenem-resistant Klebsiella pneumoniae isolated from intensive care units in China.Ann Transl Med. 2022 Oct;10(20):1109. doi: 10.21037/atm-22-4323. Ann Transl Med. 2022. PMID: 36388786 Free PMC article.
-
Molecular Characterization of Klebsiella pneumoniae Isolated from Sputum in a Tertiary Hospital in Xinxiang, China.Infect Drug Resist. 2022 Jul 18;15:3829-3839. doi: 10.2147/IDR.S370006. eCollection 2022. Infect Drug Resist. 2022. PMID: 35880230 Free PMC article.
-
Correlation between Drug Resistance of Klebsiella Pneumonia and Antimicrobial Drug Usage.Evid Based Complement Alternat Med. 2022 May 9;2022:2691134. doi: 10.1155/2022/2691134. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35586696 Free PMC article. Retracted.
-
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.Front Cell Infect Microbiol. 2022 Mar 15;12:823684. doi: 10.3389/fcimb.2022.823684. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35372099 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
